VIVANI MEDICAL INC (VANI)

Company Profile

Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company is headquartered in Emeryville, California and currently employs 50 full-time employees. The company went IPO on 2014-11-19. The firm develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. The company uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. NanoPortal implant technology's initial focus is on peptide therapeutics for the treatment of patients with metabolic diseases. The company operates through two segments: Biopharm Division and Neuromodulation Division. Its pipeline product candidates include NPM-119, NPM-159, NPM-139 and OKV-119. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. NPM-159 is in feasibility testing for the treatment of non-alcoholic steatohepatitis (NASH). The company is also in the development of neurostimulation systems to help patients recover critical body functions.

Company Info

VIVANI MEDICAL INC

5858 Horton Street, Suite 280

Emeryville CALIFORNIA

P: 18188335000.0

Employees: 50

Website: http://www.secondsight.com/